%0 Journal Article
%A Delgado-Valverde, Mercedes
%A Torres, Eva
%A Valiente-Mendez, Adoracion
%A Almirante, Benito
%A Gomez-Zorrilla, Silvia
%A Borrell, Nuria
%A Corzo, Juan E
%A Gurgui, Mercedes
%A Almela, Manuel
%A Garcia-Alvarez, Lara
%A Fontecoba-Sanchez, Maria Cruz
%A Martinez-Martinez, Luis
%A Canton, Rafael
%A Praena, Julia
%A Causse, Manuel
%A Gutierrez-Gutierrez, Belen
%A Roberts, Jason A
%A Farkas, Andras
%A Pascual, Alvaro
%A Rodriguez-Baño, Jesus
%T Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project.
%D 2015
%U http://hdl.handle.net/10668/9615
%X Our objective was to evaluate the impact of low versus borderline MIC of piperacillin/tazobactam on the clinical outcomes of patients with bacteraemia caused by Enterobacteriaceae who were treated with that antimicrobial. A prospective observational multicentre cohort study was conducted in 13 Spanish university hospitals. Patients >17 years old with bacteraemia due to Enterobacteriaceae who received empirical piperacillin/tazobactam treatment for at least 48 h were included. Outcome variables were clinical response at day 21, clinical response at end of treatment with piperacillin/tazobactam and all-cause 30 day mortality. Univariate and multivariate logistic regression analyses were performed. Overall, 275 patients were included in the analysis; 248 (90.2%) in the low MIC group (≤ 4 mg/L) and 27 (9.8%) in the borderline MIC group (8-16 mg/L). The biliary tract was the most common source of infection (48.4%) and Escherichia coli was the most frequent pathogen (63.3%). Crude 30 day mortality rates were 10.5% and 11.1% for the low MIC group and the borderline MIC group, respectively (relative risk = 1.06, 95% CI = 0.34-3.27, P = 1). Multivariate analysis of failure at day 21 and at end of treatment with piperacillin/tazobactam and 30 day mortality showed no trend towards increased clinical failure or mortality with borderline MICs (OR = 0.96, 95% CI = 0.18-4.88, P = 0.96; OR = 0.47, 95% CI = 0.10-2.26, P = 0.35; OR = 1.48, 95% CI = 0.33-6.68, P = 0.6). We did not find that higher piperacillin/tazobactam MIC within the susceptible or intermediate susceptibility range had a significant influence on the outcome for patients with bacteraemia due to Enterobacteriaceae.
%K Enterobacteriaceae Infections
%K Bacteremia
%K Microbial Sensitivity Tests
%K Piperacillin, Tazobactam Drug Combination
%K Survival Analysis
%~